Primary Myelofibrosis Market Report 2026

The primary myelofibrosis market size has grown strongly in recent years. It will grow from $0.84 billion in 2025 to $0.9 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to limited therapeutic options, delayed diagnosis and misdiagnosis, low disease awareness, reliance on conventional treatments, small patient population.

The primary myelofibrosis market size is expected to see strong growth in the next few years. It will grow to $1.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to development of novel targeted therapies, increasing clinical trial activities, advancements in genetic and molecular diagnostics, growing investment in hematology research, rising adoption of personalized medicine. Major trends in the forecast period include rising awareness and early diagnosis of primary myelofibrosis, growth in targeted therapies and personalized treatment approaches, increased adoption of advanced diagnostic tools, expansion of clinical trials and research activities, focus on patient support programs and disease management.

The rising prevalence of myelofibrosis is anticipated to drive the growth of the primary myelofibrosis market in the coming years. Myelofibrosis is a rare form of bone marrow cancer that interferes with normal blood cell production, causing extensive scarring of the bone marrow and leading to severe anemia, fatigue, weakness, and enlargement of the spleen. The growing prevalence of myelofibrosis is largely attributed to an aging population, as the disease most frequently affects individuals over 60 years of age, and increased life expectancy has resulted in a greater number of diagnosed cases. The increasing prevalence of myelofibrosis supports improved management of primary myelofibrosis by stimulating research efforts, enabling earlier diagnosis, expanding available treatment options, and encouraging the development of better clinical guidelines and specialized care. For instance, in November 2024, according to a report published by the National Institute for Health and Care Excellence, a UK-based independent executive non-departmental public body, myelofibrosis had a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. Therefore, the increasing prevalence of myelofibrosis is driving the growth of the primary myelofibrosis market.

Major companies operating in the primary myelofibrosis market are concentrating on the development of innovative therapies, such as Janus kinase 2 (JAK2) inhibiting tablets, to enhance symptom management and slow disease progression. JAK2 inhibiting tablets are oral drugs that block the activity of the JAK2 enzyme, which plays a key role in the abnormal signaling pathways responsible for excessive blood cell production in primary myelofibrosis. These medications help decrease spleen enlargement, relieve symptoms such as fatigue and bone pain, and delay disease progression. For example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, introduced Omjjara (momelotinib), a new therapy for myelofibrosis. The drug was approved by South Korea’s Ministry of Food and Drug Safety for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara is an oral treatment that inhibits Janus kinases (JAK1 and JAK2) as well as activin A receptor type 1 (ACVR1), effectively addressing symptoms such as anemia, splenomegaly, and fatigue. Its approval was supported by clinical trial results demonstrating meaningful improvements in anemia, spleen size, and overall symptom burden compared with existing therapies.

In September 2025, GlaxoSmithKline plc (GSK), a UK-based biopharmaceutical company, entered into a partnership with the pan-Canadian Pharmaceutical Alliance (pCPA) to expand public access to Ojjaara in Canada. Through this collaboration, the letter of intent aims to support reimbursement discussions and enhance the availability of Ojjaara for adults with myelofibrosis who suffer from moderate to severe anemia. The pan-Canadian Pharmaceutical Alliance (pCPA) is a Canada-based collaborative organization that negotiates drug pricing on behalf of provincial and territorial public drug plans.

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary myelofibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the primary myelofibrosis market by increasing the cost of imported diagnostic equipment, medications, and laboratory reagents. Segments such as targeted therapies and advanced diagnostic tools are most affected, particularly in regions like North America and Asia-Pacific, where import reliance is high. This has led to higher treatment costs and limited accessibility in certain regions. On the positive side, tariffs are encouraging local production, domestic R&D investment, and the development of cost-effective treatment alternatives.

The primary myelofibrosis market research report is one of a series of new reports that provides primary myelofibrosis market statistics, including primary myelofibrosis industry global market size, regional shares, competitors with a primary myelofibrosis market share, detailed primary myelofibrosis market segments, market trends and opportunities, and any further data you may need to thrive in the primary myelofibrosis industry. This primary myelofibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Primary myelofibrosis (PMF) is a rare, long-term bone marrow disorder marked by the excessive development of fibrous scar tissue within the bone marrow. This scarring interferes with normal blood cell formation, resulting in conditions such as anemia, weakness, fatigue, and enlargement of the spleen (splenomegaly). PMF is classified as a type of myeloproliferative neoplasm (MPN) and may also cause symptoms including night sweats, weight loss, and bone pain.

The main types of primary myelofibrosis include spinocerebellar primary myelofibrosis, primary myelofibrosis-telangiectasia, episodic primary myelofibrosis, and other variants. Services related to the condition include diagnosis and treatment, while medications are offered in multiple dosage forms such as solid, liquid, and other formulations to meet varying patient requirements. The disease affects all age groups, including adults, children, and the elderly, and is managed across different end-user settings such as hospitals, clinics, and other healthcare facilities.

The primary myelofibrosis market consists of revenues earned by entities by providing services such as diagnosis services, medical consultations, treatment services, monitoring and follow-up and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary myelofibrosis (PMF) market also includes sales of products including ruxolitinib (Jakafi or Jakavi), erythropoiesis-stimulating agents (ESAs), hydroxyurea, bone marrow or stem cell transplant kits and iron supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.